Expert Interview
A Second View: Discussing the updated Phase 1B data for Celldex' barzolvolimab in chronic spontaneous urticaria (CSU) with a community immunologist
Ticker(s): CLDXInstitution: Aurora Allergy
- Board certified Allergist and Immunologist at Aurora Allergy (WI) in practice for nearly 20 years.
- Treats 75 patients with moderate to severe chronic spontaneous urticaria (CSU) that are refractory to antihistamines.
- Clinical focus on asthma, allergic rhinitis, and selective polysaccharide antibody deficiency.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
